Stanley Yu

Dr Stanley Yu

School of Medicine

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Available For Media Comment.


I hold a PhD in Medical Virology from Wuhan University, China, completed as a joint program with the University of Hong Kong. In late 2010, I immigrated to Australia and began working in Professor Eric Gowans’ HCV laboratory (2011–2014). Since 2015, I have been a member of Professor Michael Brown’s Translational Oncology laboratory, focusing on cancer immunotherapy research. I am an enthusiastic scientist with over 22 years of laboratory experience, 40 peer-reviewed publications, more than 1,200 citations, and an H-index of 18.

My research interests broadly include persistent viral infections, immunology, cancer immunotherapy, and aging biology. My current research primarily focuses on CAR-T therapy. I also have a strong interest in theoretical biology and have proposed an aging hypothesis known as the “np theory.”

Date Position Institution name
2023 - ongoing Affiliate Senior Lecturer University of Adelaide
2015 - ongoing Research Officer Centre for Cancer Biology
2011 - 2014 Research Officer Basil Hetzel Institute
2008 - 2011 Research Assistant University of Hong Kong

Language Competency
Chinese (Mandarin) Can read, write, speak, understand spoken and peer review
English Can read, write, speak, understand spoken and peer review

Date Institution name Country Title
2004 - 2010 Wuhan University China PhD
2000 - 2004 Wuhan University China Bachelor of Science

Year Citation
2024 Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659-1-e008659-17.
DOI Scopus42 WoS40 Europe PMC31
2024 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
DOI Scopus12 WoS11 Europe PMC10
2023 Yu, W., Gargett, T., & Du, Z. (2023). A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging. Aging, 15(17), 8537-8551.
DOI Scopus2 WoS3 Europe PMC1
2022 Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
DOI Scopus93 WoS91 Europe PMC89
2021 El Khawanky, N., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., . . . Zeiser, R. (2021). Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun, 12(1), 6436-1-6436-20.
DOI Scopus94 WoS91 Europe PMC89
2020 Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
DOI Scopus58 WoS56 Europe PMC53
2020 Mekonnen, Z. A., Masavuli, M. G., Yu, W., Gummow, J., Whelan, D. M., Al-Delfi, Z., . . . Grubor-Bauk, B. (2020). Enhanced T cell responses induced by a necrotic dendritic cell vaccine, expressing HCV NS3. Front Microbiol, 11(559105), 1-13.
DOI Scopus8 WoS6 Europe PMC7
2019 Gargett, T., TRUONG, N., EBERT, L., YU, W., & BROWN, M. (2019). Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 21(6), 593-602.
DOI Scopus34 WoS33 Europe PMC37
2018 Wijesundara, D., Gummow, J., Li, Y., Yu, W., Quah, B., Ranasinghe, C., . . . Grubor-Bauk, B. (2018). Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. Journal of Virology, 92(8), 1-15.
DOI Scopus22 WoS23 Europe PMC23
2018 Ebert, L. M., Yu, W., Gargett, T., & Brown, M. P. (2018). Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 46(2), 391-401.
DOI Scopus30 WoS29 Europe PMC25
2017 Hughes, A. E., Clarson, J., Gargett, T., Yu, W., Brown, M. P., Lopez, A. F., . . . Yong, A. S. M. (2017). Comment on 'KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study'. Leukemia research, 55, 55-57.
DOI Scopus3 WoS3 Europe PMC3
2017 Wijesundara, D., Yu, W., Quah, B., Eldi, P., Hayball, J., Diener, K., . . . Grubor-Bauk, B. (2017). Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner. Scientific Reports, 7(1), 8530-1-8530-8.
DOI Scopus8 WoS9 Europe PMC9
2016 Grubor-Bauk, B., Yu, W., Wijesundara, D., Gummow, J., Garrod, T., Brennan, A., . . . Gowans, E. (2016). Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Therapy, 23(1), 26-37.
DOI Scopus25 WoS24 Europe PMC25
2016 Gargett, T., Yu, W., Dotti, G., Yvon, E., Christo, S., Hayball, J., . . . Brown, M. (2016). GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Molecular Therapy, 24(6), 1135-1149.
DOI Scopus329 WoS304 Europe PMC292
2015 Tomusange, K., Yu, W., Suhrbier, A., Wijesundara, D., Grubor-Bauk, B., & Gowans, E. (2015). Engineering human rhinovirus serotype-A1 as a vaccine vector. Virus Research, 203, 72-76.
DOI Scopus7 WoS6 Europe PMC4
2015 Gummow, J., Li, Y., Yu, W., Garrod, T., Wijesundara, D., Brennan, A., . . . Gowans, E. (2015). A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-Cell responses in mice. Journal of Virology, 89(15), 7991-8002.
DOI Scopus24 WoS26 Europe PMC24
2014 Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 10(12), 3576-3578.
DOI WoS2
2014 Yu, W., Grubor-Bauk, B., Gargett, T., Garrod, T., & Gowans, E. (2014). A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. Vaccine, 32(27), 3409-3416.
DOI Scopus17 WoS16 Europe PMC12
2014 Garrod, T., Gargett, T., Yu, W., Major, L., Burrell, C., Wesselingh, S., . . . Gowans, E. (2014). Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Research, 192, 25-33.
DOI Scopus6 WoS6 Europe PMC7
2014 Garrod, T., Grubor-Bauk, B., Gargett, T., Li, Y., Miller, D., Yu, W., . . . Gowans, E. (2014). DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. European Journal of Immunology, 44(7), 1992-2002.
DOI Scopus24 WoS21 Europe PMC19
2014 Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T., & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. Human Vaccines and Immunotherapeutics, 10(9), 2679-2683.
DOI Scopus10 WoS11 Europe PMC9
2014 Gargett, T., Grubor-Bauk, B., Garrod, T., Yu, W., Miller, D., Major, L., . . . Gowans, E. (2014). Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunology and Cell Biology, 92(4), 359-367.
DOI Scopus24 WoS25 Europe PMC25
2014 Gargett, T., Grubor-Bauk, B., Miller, D., Garrod, T., Yu, S., Wesselingh, S., . . . Gowans, E. (2014). Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clinical and Translational Immunology, 3(6), e18-1-e18-7.
DOI Scopus24 WoS21 Europe PMC20
2014 Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. Human vaccines & immunotherapeutics, 10(12), 3576-3578.
DOI Scopus3 Europe PMC3
2013 Zhou, J., Cheung, A. K. L., Tan, Z., Wang, H., Yu, W., Du, Y., . . . Chen, Z. (2013). PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8(+) T cells in mice. Journal of clinical investigation, 123(6), 2629-2642.
DOI Scopus65 Europe PMC53
2013 Xiao, H., Liu, L., Zhu, Q., Tan, Z., Yu, W., Tang, X., . . . Chen, Z. (2013). A replicating modified Vaccinia Tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLoS One, 8(12, article no. e83273), 1-10.
DOI Scopus10 Europe PMC8
2011 Yu, W. B., Liu, L., & Chen, Z. W. (2011). Attenuation of the smallpox vaccine Vaccinia Tiantan strain and its use as a safe vaccine live vector. Chinese journal of viral diseases, 1(1), 75-80.
2011 Lu, B., Yu, W., Huang, X., Wang, H., Liu, L., & Chen, Z. (2011). Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: Vaccinia Tiantan strain. Journal of biomedicine and biotechnology, 2011(970424), 1-9.
DOI
2010 Liu, H., Yu, W., Tang, X., Wang, H., Ouyang, W., Zhou, J., & Chen, Z. (2010). The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice. Journal of medical virology, 82(5), 727-734.
DOI Scopus13 Europe PMC13
2009 Huang, X., Lu, B., Yu, W., Fang, Q., Liu, L., Zhuang, K., . . . Chen, Z. (2009). A novel replication-competent vaccinia vector MVTT Is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One, 4(1, article no. e4180), 1-9.
DOI Scopus45 Europe PMC39
2009 Yu, W., Fang, Q., Zhu, W., Wang, H., Tien, P., Zhang, L., & Chen, Z. (2009). One time intranasal vaccination with a modified vaccinia Tiantan strain MVTTZCI protects animals against pathogenic viral challenge. Vaccine, 28(9), 2088-2096.
DOI Scopus22 Europe PMC19
2007 Zhu, W., Fang, Q., Zhuang, K., Wang, H., Yu, W., Zhou, J., . . . Chen, Z. (2007). The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. Journal of Virological Methods, 144(1-2), 17-26.
DOI Scopus32 Europe PMC26
2005 Fang, Q., Yang, L., Zhu, W., Liu, L., Wang, H., Yu, W., . . . Chen, Z. (2005). Host range, growth property, and virulence of the smallpox vaccine: Vaccinia virus Tian Tan strain. Virology, 335(2), 242-251.
DOI Scopus58 Europe PMC53

Year Citation
2019 El Khawanky, N., Hughes, A., Yu, W., Taromi, S., Clarson, J., Lopez, A. F., . . . Zeiser, R. (2019). Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS4
2017 El-Khawanky, N., Hughes, A., Yu, W., Clarson, J., Lopez, A. F., Brown, M., . . . Yong, A. (2017). CD123 Chimeric Antigen Receptor T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of HAA.
2017 El-Khawanky, N., Hughes, T. P., Clarson, J., Yu, W., White, D. L., & Yong, A. (2017). Anti-CD123 Chimeric Antigen Receptor (CAR) T-cells in Chronic and Acute Myeloid Leukaemia: pre-clinical in vitro studies. Poster session presented at the meeting of ASMR.

Year Citation
2026 Yu, W. (2026). A Reflection on Theories of Aging.
DOI
2023 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M., Pitson, S., . . . Brown, M. (2023). Endogenous bystander killing mechanisms enhance the activity of novel FAP-specific CAR-T cells against glioblastoma.
DOI
  • Principle investigator:Wenbo Yu. RAH research committee 2019 Clinical project grant: USING CRISPR/CAS9 GENE-EDITING TECHNOLOGY TO TURN EFFECTOR CAR CELLS. 2019
  • Associate investigator: Wenbo Yu. The Ray Shirl Norman Cancer Research Trust RESEARCH GRANT: Development of new combination immunotherapies for glioblastoma based on Chimeric Antigen Receptor (CAR)-T cell and Bispecific T cell Engager (BiTE) technologies. 2021-2023
  • Chief investigator (CI 4): Wenbo Yu. 2020 Mark Hughes Foundation Brain Cancer Innovation Project Grants. Using the immune system to target and destroy blood vessels feeding aggressive brain tumours. 2021-2023
  • Chief investigator (CI C): Wenbo Yu. NHMRC: Priority-driven Collaborative Cancer Research Scheme (PdCCRS) 2020: A new gene modification strategy for generating optimised CAR-T cells for therapy of glioblastoma. 2021-2024
  • Chief investigator (CI C): Wenbo Yu. The Ray Shirl Norman Cancer Research Trust RESEARCH GRANT 2023: CAR-T-mediated bystander killing overcomes tumour antigen heterogeneity - the major limitation of CAR-T cell therapy for solid tumours. 2024-2026

Date Topic Presented at Institution Country
2023 - 2023 Poisson Distribution-Based Model of Cancer Rates & Risk-Dependent Theory of Aging Aging-US online Centre for Cancer Biology Australia

Connect With Me

External Profiles

Other Links